Cantor Fitzgerald Estimates Tourmaline Bio FY2025 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Cantor Fitzgerald issued their FY2025 earnings estimates for Tourmaline Bio in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($3.48) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($2.99) per share.

Tourmaline Bio (NASDAQ:TRML) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.06.

A number of other research analysts have also recently issued reports on TRML. HC Wainwright reiterated a “buy” rating and issued a $49.00 target price on shares of Tourmaline Bio in a research report on Wednesday, December 11th. BMO Capital Markets started coverage on shares of Tourmaline Bio in a research report on Friday, December 6th. They set an “outperform” rating and a $50.00 price objective for the company. Finally, Guggenheim restated a “buy” rating on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Tourmaline Bio presently has a consensus rating of “Buy” and an average price target of $54.00.

Tourmaline Bio Stock Performance

Shares of TRML stock opened at $17.64 on Wednesday. Tourmaline Bio has a fifty-two week low of $12.12 and a fifty-two week high of $48.31. The stock’s fifty day moving average price is $22.01 and its two-hundred day moving average price is $20.99. The company has a market cap of $452.29 million, a PE ratio of -6.26 and a beta of 2.36.

Institutional Investors Weigh In On Tourmaline Bio

A number of institutional investors have recently added to or reduced their stakes in TRML. SG Americas Securities LLC grew its stake in shares of Tourmaline Bio by 3.4% in the fourth quarter. SG Americas Securities LLC now owns 34,812 shares of the company’s stock worth $706,000 after purchasing an additional 1,140 shares during the last quarter. Brooklyn Investment Group bought a new stake in shares of Tourmaline Bio in the 4th quarter valued at about $32,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Tourmaline Bio by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,932 shares of the company’s stock valued at $127,000 after buying an additional 1,920 shares during the period. JPMorgan Chase & Co. increased its position in Tourmaline Bio by 16.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,804 shares of the company’s stock valued at $381,000 after purchasing an additional 2,100 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Tourmaline Bio by 3.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,571 shares of the company’s stock worth $1,634,000 after purchasing an additional 2,147 shares during the last quarter. 91.89% of the stock is owned by institutional investors.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.